Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.
Kurome Therapeutics is a preclinical stage company that is developing a series of IRAK1/4, panFLT3 inhibitors. Preclinical studies have demonstrated:
-Broad range of efficacy in MDS and AML patient-derived cell lines
-Synergy with Venclexta® (Venetoclax) to improve Venclexta® potency
-Identification of a biomarker that correlates with prognosis in AML patients and maximal activation of immune signaling through this pathway in AML cells
-Increased overall survival in cell line and patient-derived xenograft models, well beyond that of existing FLT3 inhibitors
-Maintenance of complete efficacy even in settings of adaptive resistance to FLT3 inhibitors and in settings of FLT3 mutations
Kurome Therapeutics is founded on research developed in the laboratory of Dr. Daniel Starczynowski at Cincinnati Children's Hospital Medical Center in collaboration with the National Center for Advancing Translational Sciences (NCATS) at the NIH.